Experimental Hematology
Volume 37, Issue 1 , Pages 78-86, January 2009

Identification of primary MAFB target genes in multiple myeloma

  • Esther van Stralen

      Affiliations

    • University Medical Center Utrecht, Department of Immunology, Utrecht, The Netherlands
    • Hubrecht Laboratory, Center for Biomedical Genetics, Utrecht, The Netherlands
  • ,
  • Marc van de Wetering

      Affiliations

    • Hubrecht Laboratory, Center for Biomedical Genetics, Utrecht, The Netherlands
  • ,
  • Luca Agnelli

      Affiliations

    • Laboratory of Molecular Genetics and Gene Expression, Fondazione IRCCS Policlinico, Milan, Italy
  • ,
  • Antonino Neri

      Affiliations

    • Laboratory of Molecular Genetics and Gene Expression, Fondazione IRCCS Policlinico, Milan, Italy
    • Department of Medical Sciences, University of Milan, Milan, Italy
  • ,
  • Hans C. Clevers

      Affiliations

    • Hubrecht Laboratory, Center for Biomedical Genetics, Utrecht, The Netherlands
  • ,
  • Bert J.E.G. Bast

      Affiliations

    • University Medical Center Utrecht, Department of Immunology, Utrecht, The Netherlands
    • Corresponding Author InformationCorrespondence: Bert Bast, Ph.D., Department of Immunology, University Medical Centre Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands

Received 1 April 2008; received in revised form 25 August 2008; accepted 25 August 2008. published online 14 November 2008.

Objective

In multiple myeloma (MM), seven primary recurrent translocations involving the immunoglobulin heavy chain locus have been identified. One of the partner loci maps to 20q12 and involves the MAFB gene resulting in its ectopic expression. We attempt here to identify MAFB target genes in MM.

Materials and Methods

We used an inducible system to upregulate MAFB in MM cell lines not carrying the t(14;20). Microarray expression analysis was used to detect gene expression changes upon MAFB expression. These genes were further evaluated comparatively with gene expression profiles obtained from MM or plasma cell leukemia tumors carrying an activated MAFB gene. Functional implications of these upregulated genes were studied by testing their promoter activity in reporter assays. C-MAF was included comparatively as well.

Results

The inducible cell lines identified a total of 284 modulated transcripts. After further evaluation using ex vivo data 14 common upregulated genes were found, common to the C-MAF pathway as well. The promoter activity of some of these secondary genes proved a functional relationship with MAFB. In connection with one of these secondary genes (NOTCH2), even tertiary upregulated genes were found. Functional studies indicated that inducible MAFB expression conferred antiapoptotic effects.

Conclusion

We identified 14 upregulated genes, and their downstream consequences in the combined MAFB/C-MAF pathway. Eleven of these genes are novel in the C-MAF pathway as well. These direct target genes may be responsible for the oncogenic transformation of MAF expressing myeloma cells.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0301-472X(08)00413-X

doi:10.1016/j.exphem.2008.08.006

Experimental Hematology
Volume 37, Issue 1 , Pages 78-86, January 2009